THE EFFICACY OF N-ACETYL CYSTEINE AS AN ADJUNCTIVE TREATMENT FOR FIRST EPISODE PSYCHOSIS
Grant number: 1125778 | Funding period: 2017 - 2022
First episode psychosis may foreshadow devastating, chronic illness. Psychosis follows a staged, progressive pathway. There is evidence to suggest illness progression can be diminished and perhaps even averted if appropriate treatments are given at the early stages of illness. This project will test if N-acetycysteine (NAC) administered to young people who have experienced a first episode of psychosis can help prevent this early psychotic experience from developing into a chronic disorder.
Related publications (1)
ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis
SM Cotton, M Berk, A Watson, S Wood, K Allott, CF Bartholomeusz, CC Bortolasci, K Walder, B O'Donoghue, OM Dean, A Chanen, GP Amminger, PD McGorry, A Burnside, J Uren, A Ratheesh, S Dodd
BACKGROUND: First-episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, ..